Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives

Keywords

Philosophy

References

• Environmentally relevant xenoestrogen tissue concentrations correlated to biological responses in mice.Alix Peterson Zwane, Jonathan Zinman, Eric Van Dusen — 2000
• HEALTHY AGING : A WOMEN'S ISSUEAndrea Z. La Croix, Katherine M. Newton, Suzanne G. Leveille — 1997
• Ovaries to Estrogen: Sex Hormones and Chemical Femininity in the 20th CenturyBernice L. Hausman — 1999
• The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth By Barbara SeamanC. Dominique Toran‐Allerand — 2004
• Encyclopedia of hormonesHenry, Helen L. — 2003
• The politics of women's biologyRuth Hubbard — 1990
• Our Stolen FutureTheo Colborn, Dianne Dumanoski, John Peterson Myers — 1996
• Women And The Crisis In Sex HormonesBarbara Seaman, Gideon Seaman — 1977
• Seizing our bodies : the politics of women's healthClaudia Dreifus — 1977
• On the pill : a social history of oral contraceptives in America, 1950-1970Elizabeth Rose Siegel Watkins — 1996
• Endocrinology of neoplastic diseaseRyan Frank — 1948
• A REVIEW OF POSTMENOPAUSAL HORMONE THERAPY RECOMMENDATIONS: POTENTIAL FOR SELECTION BIASElina Hemminki, Sinikka Sihvo — 1993
• Management of menopause-related symptoms.Heidi D Nelson, Elizabeth M Haney, Laura Humphrey — 2005
• A Comparison of Conditions Associated with Breast Cancer in Great Britain and AmericaJonathan M. Wainwright — 1931
• Relationship of Hormones and Mammary Adenocarcinoma in the MouseA Lacassagne — 1939
• The Truth about Drug Companies: How They Deceive Us and What to Do about ItTyler Cymet — 2006
• Women and health in America : historical readingsJudith Walzer Leavitt — 1999
• Disempowering midlife womenRenate Klein, Lynette J. Dumble — 1994
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.Writing Group for the Women's Health Initiative Investigators — 2002
• Between monsters, goddesses, and cyborgs : feminist confrontations with science, medicine, and cyberspaceNina Lykke, Rosi Braidotti — 1996

Cited by

• Theorizing Social Context: Rethinking Behavioral TheoryPeter Hill — 2009
• The irreducibility of value-freedom to theory assessment.Paolo Mastandrea — 2015
• Women’s Health Movements: A Global Force for ChangeMeredeth Turshen — 2007
• Sesgos de género en investigación clínica, marketing farmacéutico y prescripción de medicamentosElisa Chilet‐Rosell — 2013
• How Do You Know Which Health Care Effectiveness Research You Can Trust? A Guide to Study Design for the PerplexedStephen B. Soumerai, Douglas Starr, Sumit R. Majumdar — 2015
• Medical decisions, estrogen and agingJay Schulkin — 2007
• Menopausal hormone therapy for the primary prevention of chronic conditions. U.S. Preventive Services Task Force recommendation statement.Catherine Kreatsoulas, Sonia S. Anand — 2013
• Hormone Replacement Therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in SpainElisa Chilet‐Rosell, Marta Martín Llaguno, María Teresa Ruiz‐Cantero — 2010
• Negotiating Competing Discourses: The Decision to Take Menopausal Hormone Therapy Following Surgical MenopauseBeverley Burrell, Vivienne Valledor, Marie Crowe — 2010
• Naringin protects human adipose-derived mesenchymal stem cells against hydrogen peroxide-induced inhibition of osteogenic differentiation.Lei Wang, Yuge Zhang, Xiumei Wang — 2015
• Evidence-Based Medicine, Postmenopausal Hormone Therapy, and the Women's Health InitiativePaula S. Derry — 2015
• Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid‐derived stem cellsMeimei Liu, Yan Li, Shang‐Tian Yang — 2017
• Bioidentical Hormones, Menopausal Women, and the Lure of the “Natural” in U.S. Anti-Aging MedicineJennifer R. Fishman, Michael A. Flatt, Richard A. Settersten — 2015
• Decline in US Breast Cancer Rates After the Women’s Health Initiative: Socioeconomic and Racial/Ethnic DifferentialsNancy Krieger, Jarvis T. Chen, Pamela D. Waterman — 2010
• Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort.Gita D. Mishra, Helen S. Kok, Russell Ecob — 2006
• Use of hormone replacement therapy (HRT) among women aged 45-64 years in the German EPIC-cohorts.Gabriele Nagel, Petra H. Lahmann, Mandy Schulz — 2007
• Breast Cancer and Hormones: What Have We Learned from the Women's Health Initiative?Jennifer Hays — 2006
• The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?Steven Fishbane, Allen R. Nissenson — 2007
• Attitudes towards the menopause and hormone therapy over the turn of the century.Lotta Lindh‐Åstrand, Jan Brynhildsen, Mikael Hoffmann — 2007
• State of the Evidence: The Connection Between Breast Cancer and the EnvironmentJanet Gray, Nancy Evans, Brynn Taylor — 2009

Related papers

No related papers recorded.